Annual report [Section 13 and 15(d), not S-K Item 405]

Leases

v3.25.4
Leases
 12 Months Ended
Dec. 31, 2025
Leases [Abstract]  
Leases Leases
As Lessee:
The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.
The components of the Company’s operating lease costs consisted of the following (in thousands):
Years Ended December 31,
2025 2024
Operating lease cost $ 1,989  $ 1,910 
Variable lease cost 460  359 
Total lease cost $ 2,449  $ 2,269 
Lease costs for the years ended December 31, 2025 and 2024 of approximately $2.4 million and $2.3 million, respectively, were recorded to G&A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $0.8 million and nil for the fiscal years ended December 31, 2025, and 2024, respectively.
Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands):
Years Ended December 31,
2025 2024
Cash paid for amounts included in the measurement of lease liabilities and right of use assets:
Operating cash flow from operating leases $ 2,025  $ 1,863 
Right of use assets obtained in exchange for lease obligations:
Operating leases $ 37  $ 250 
Increases to right of use assets resulting from lease modifications:
Operating leases $ 344  $ — 
Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows:
2025 2024
Years Years
Weighted average remaining lease term: 4.5 5.3
Rate Rate
Weighted average discount rate: 7.7% 7.9%
Future maturities of lease liabilities as of December 31, 2025 are as follows (in thousands):
Operating Leases
2026 $ 1,903 
2027 1,627 
2028 1,504 
2029 1,396 
2030 818 
Thereafter 273 
Total undiscounted lease payments 7,521 
Less: Imputed interest (2,706)
Total lease liabilities $ 4,815 
The long-term portion of the lease liabilities included in the amounts above is $3.4 million with the remainder included in other current liabilities in the Consolidated Balance Sheets.
As Lessor
We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the “combining lease and non-lease components” practical expedient for all qualifying non-lease components.
The components of the Company’s lease revenues consisted of the following (in thousands):
Years Ended December 31,
2025 2024
Net operating lease revenue
 $ 30,006  $ 27,843 
Sales-type lease revenue 350  717 
Total lease revenue $ 30,356  $ 28,560 
The components of our net investment in sales-type leases as of December 31, 2025 and 2024 were (in thousands):

2025 2024
Lease receivable $ 1,905  $ 1,934 
Net investment in leases $ 1,905  $ 1,934 

Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December 31, 2025 and 2024 (in thousands):

2025 2024
Accounts receivable, net $ 563  $ 1,207 
Other assets 1,342  727 
Total $ 1,905  $ 1,934 

Future maturities of sales-type leases as of December 31, 2025 are as follows (in thousands):
Sales-Type Leases
2026 $ 807 
2027 658 
2028 562 
2029 408 
Total undiscounted lease payments 2,435 
Less: Imputed interest (530)
Total lease receivables $ 1,905 
Leases Leases
As Lessee:
The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases.
The components of the Company’s operating lease costs consisted of the following (in thousands):
Years Ended December 31,
2025 2024
Operating lease cost $ 1,989  $ 1,910 
Variable lease cost 460  359 
Total lease cost $ 2,449  $ 2,269 
Lease costs for the years ended December 31, 2025 and 2024 of approximately $2.4 million and $2.3 million, respectively, were recorded to G&A expenses. Expense related to short-term leases, which are not recorded on the Company's consolidated balance sheets, was $0.8 million and nil for the fiscal years ended December 31, 2025, and 2024, respectively.
Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands):
Years Ended December 31,
2025 2024
Cash paid for amounts included in the measurement of lease liabilities and right of use assets:
Operating cash flow from operating leases $ 2,025  $ 1,863 
Right of use assets obtained in exchange for lease obligations:
Operating leases $ 37  $ 250 
Increases to right of use assets resulting from lease modifications:
Operating leases $ 344  $ — 
Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows:
2025 2024
Years Years
Weighted average remaining lease term: 4.5 5.3
Rate Rate
Weighted average discount rate: 7.7% 7.9%
Future maturities of lease liabilities as of December 31, 2025 are as follows (in thousands):
Operating Leases
2026 $ 1,903 
2027 1,627 
2028 1,504 
2029 1,396 
2030 818 
Thereafter 273 
Total undiscounted lease payments 7,521 
Less: Imputed interest (2,706)
Total lease liabilities $ 4,815 
The long-term portion of the lease liabilities included in the amounts above is $3.4 million with the remainder included in other current liabilities in the Consolidated Balance Sheets.
As Lessor
We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the “combining lease and non-lease components” practical expedient for all qualifying non-lease components.
The components of the Company’s lease revenues consisted of the following (in thousands):
Years Ended December 31,
2025 2024
Net operating lease revenue
 $ 30,006  $ 27,843 
Sales-type lease revenue 350  717 
Total lease revenue $ 30,356  $ 28,560 
The components of our net investment in sales-type leases as of December 31, 2025 and 2024 were (in thousands):

2025 2024
Lease receivable $ 1,905  $ 1,934 
Net investment in leases $ 1,905  $ 1,934 

Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as of December 31, 2025 and 2024 (in thousands):

2025 2024
Accounts receivable, net $ 563  $ 1,207 
Other assets 1,342  727 
Total $ 1,905  $ 1,934 

Future maturities of sales-type leases as of December 31, 2025 are as follows (in thousands):
Sales-Type Leases
2026 $ 807 
2027 658 
2028 562 
2029 408 
Total undiscounted lease payments 2,435 
Less: Imputed interest (530)
Total lease receivables $ 1,905